Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of PCI-24781 Administered Orally in Patients With Advanced Cancer.

Trial Profile

Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of PCI-24781 Administered Orally in Patients With Advanced Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Nov 2016

At a glance

  • Drugs Abexinostat (Primary)
  • Indications Chronic lymphocytic leukaemia; Hodgkin's disease; Multiple myeloma; Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Pharmacyclics
  • Most Recent Events

    • 26 Sep 2011 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.
    • 26 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Dec 2009 Planned end date changed from 1 Sep 2009 to 1 Mar 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top